Sientra
- Home ›
- US ›
- Healthcare
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. The last earnings update was 40 days ago. More info.
Add to Portfolio Compare Print
- Sientra has significant price volatility in the past 3 months.
SIEN Share Price and Events
7 Day Returns
1 Year Returns
SIEN Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Sientra (SIEN) | 3.4% | -8.9% | -26.6% | -68% | -2.6% | - |
| US Medical Equipment | 0.7% | 5% | 1.5% | 12.2% | 63.1% | 94.2% |
| US Market | 0.5% | -0.1% | 1% | 0.8% | 37.5% | 37.5% |
1 Year Return vs Industry and Market
- SIEN underperformed the Medical Equipment industry which returned 12.2% over the past year.
- SIEN underperformed the Market in United States of America which returned 0.8% over the past year.
SIEN Value
Is Sientra undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Sientra
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Sientra.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 9 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 8.6% |
| Perpetual Growth Rate | 10-Year US Government Bond Rate | 2.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year US Govt Bond Rate | 2.7% |
| Equity Risk Premium | S&P Global | 6% |
| Medical Equipment Unlevered Beta | Simply Wall St/ S&P Global | 0.85 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.852 (1 + (1- 21%) (18.77%)) |
0.985 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
0.99 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.985 * 5.96%) |
8.6% |
Discounted Cash Flow Calculation for NasdaqGS:SIEN using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Sientra is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
| Levered FCF (USD, Millions) | Source |
Present Value Discounted (@ 8.6%) |
|
|---|---|---|---|
| 2019 | -77.00 | Analyst x1 | -70.90 |
| 2020 | -70.00 | Analyst x1 | -59.35 |
| 2021 | -43.00 | Analyst x1 | -33.57 |
| 2022 | 0.00 | Analyst x1 | 0.00 |
| 2023 | 28.00 | Analyst x1 | 18.53 |
| 2024 | 46.98 | Est @ 67.79% | 28.64 |
| 2025 | 69.66 | Est @ 48.27% | 39.09 |
| 2026 | 93.76 | Est @ 34.61% | 48.46 |
| 2027 | 117.24 | Est @ 25.04% | 55.79 |
| 2028 | 138.76 | Est @ 18.35% | 60.80 |
| Present value of next 10 years cash flows | $87.49 | ||
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2028
× (1 + g) ÷ (Discount Rate – g)
= $138.76 × (1 + 2.73%) ÷ (8.6% – 2.73%) |
$2,427.84 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)10
= $2,427.84 ÷ (1 + 8.6%)10 |
$1,063.82 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 10 years cash flows +
Terminal Value
= $87.49 + $1,063.82 |
$1,151.31 |
| Equity Value per Share (USD) |
= Total value / Shares Outstanding
= $1,151.31 / 49.22 |
$23.39 |
| Calculation | Result | |
|---|---|---|
| Value per share (USD) | From above. | $23.39 |
| Current discount | Discount to share price of
$6.47
= -1 x ($6.47 - $23.39) / $23.39 |
72.3% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Sientra's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Sientra's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Sientra's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Sientra's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in USD | $-3.23 |
| NasdaqGS:SIEN Share Price ** | NasdaqGS (2019-06-14) in USD | $6.47 |
| United States of America Medical Equipment Industry PE Ratio | Median Figure of 64 Publicly-Listed Medical Equipment Companies | 40.75x |
| United States of America Market PE Ratio | Median Figure of 3,094 Publicly-Listed Companies | 17.69x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Sientra.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGS:SIEN Share Price ÷ EPS (both in USD) = 6.47 ÷ -3.23 |
-2x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sientra is loss making, we can't compare its value to the US Medical Equipment industry average.
- Sientra is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
Sientra's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -2x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts |
41.6%per year |
| United States of America Medical Equipment Industry PEG Ratio | Median Figure of 55 Publicly-Listed Medical Equipment Companies | 2.25x |
| United States of America Market PEG Ratio | Median Figure of 2,125 Publicly-Listed Companies | 1.52x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Sientra, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Sientra's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in USD | $1.45 |
| NasdaqGS:SIEN Share Price * | NasdaqGS (2019-06-14) in USD | $6.47 |
| United States of America Medical Equipment Industry PB Ratio | Median Figure of 183 Publicly-Listed Medical Equipment Companies | 4.36x |
| United States of America Market PB Ratio | Median Figure of 5,244 Publicly-Listed Companies | 1.79x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGS:SIEN Share Price ÷ Book Value per Share (both in USD) = 6.47 ÷ 1.45 |
4.47x |
* Primary Listing of Sientra.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sientra is overvalued based on assets compared to the US Medical Equipment industry average.
Value checks
We assess Sientra's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Sientra has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
SIEN Future Performance
How is Sientra expected to perform in the next 1 to 3 years based on estimates from 9 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Sientra's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- Sientra's earnings growth is expected to exceed the United States of America market average.
- Sientra's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGS:SIEN Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts | 41.6% |
| NasdaqGS:SIEN Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts | 24.2% |
| United States of America Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 21.9% |
| United States of America Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 7.9% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.9% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.3% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 9 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 221 | 9 | 1 | |
| 2022-12-31 | 180 | -17 | 1 | |
| 2021-12-31 | 145 | -32 | -46 | 5 |
| 2020-12-31 | 107 | -52 | -72 | 9 |
| 2019-12-31 | 81 | -66 | -89 | 9 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 71 | -68 | -90 |
| 2018-12-31 | 68 | -56 | -83 |
| 2018-09-30 | 60 | -52 | -76 |
| 2018-06-30 | 53 | -61 | -70 |
| 2018-03-31 | 44 | -50 | -72 |
| 2017-12-31 | 37 | -46 | -64 |
| 2017-09-30 | 32 | -43 | -54 |
| 2017-06-30 | 29 | -31 | -50 |
| 2017-03-31 | 27 | -30 | -40 |
| 2016-12-31 | 21 | -34 | -40 |
| 2016-09-30 | 16 | -38 | -60 |
| 2016-06-30 | 19 | -31 | -57 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (2 months ago) | See Below |
| Future Estimates | Average of up to 9 Analyst Estimates (S&P Global) | See Below |
All data from Sientra Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 0.19 | 0.19 | 0.19 | 1.00 |
| 2022-12-31 | -0.35 | -0.35 | -0.35 | 1.00 |
| 2021-12-31 | -1.12 | -0.67 | -1.66 | 5.00 |
| 2020-12-31 | -1.96 | -1.29 | -2.91 | 8.00 |
| 2019-12-31 | -2.75 | -2.17 | -3.43 | 8.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2019-03-31 | -3.23 |
| 2018-12-31 | -3.25 |
| 2018-09-30 | -3.29 |
| 2018-06-30 | -3.35 |
| 2018-03-31 | -3.72 |
| 2017-12-31 | -3.34 |
| 2017-09-30 | -2.86 |
| 2017-06-30 | -2.67 |
| 2017-03-31 | -2.15 |
| 2016-12-31 | -2.20 |
| 2016-09-30 | -3.34 |
| 2016-06-30 | -3.29 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Sientra will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Sientra's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Sientra has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
SIEN Past Performance
How has Sientra performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Sientra does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Sientra's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Sientra's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Sientra Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 71.00 | -89.69 | 117.16 | 11.25 |
| 2018-12-31 | 68.13 | -82.63 | 107.61 | 10.95 |
| 2018-09-30 | 60.17 | -75.83 | 95.44 | 10.07 |
| 2018-06-30 | 53.11 | -69.67 | 82.75 | 10.10 |
| 2018-03-31 | 43.73 | -72.03 | 72.02 | 9.37 |
| 2017-12-31 | 36.54 | -64.03 | 61.21 | 9.81 |
| 2017-09-30 | 31.97 | -54.26 | 50.66 | 10.01 |
| 2017-06-30 | 28.68 | -49.85 | 47.51 | 9.15 |
| 2017-03-31 | 26.75 | -39.65 | 45.26 | 10.64 |
| 2016-12-31 | 20.73 | -40.17 | 42.27 | 9.70 |
| 2016-09-30 | 15.78 | -60.34 | 45.27 | 9.67 |
| 2016-06-30 | 19.18 | -56.98 | 44.87 | 9.76 |
| 2016-03-31 | 27.14 | -49.78 | 44.22 | 8.20 |
| 2015-12-31 | 38.11 | -41.23 | 44.50 | 7.20 |
| 2015-09-30 | 48.69 | -16.18 | 42.09 | 6.05 |
| 2015-06-30 | 49.43 | -11.03 | 39.01 | 5.16 |
| 2015-03-31 | 46.94 | -8.19 | 37.05 | 4.77 |
| 2014-12-31 | 44.73 | -5.81 | 34.31 | 4.71 |
| 2014-09-30 | 41.87 | -5.69 | 32.85 | 4.63 |
| 2014-06-30 | 39.18 | -10.71 | 31.81 | 4.62 |
| 2014-03-31 | 36.94 | -16.02 | 30.43 | 4.59 |
| 2013-12-31 | 35.17 | -19.13 | 39.11 | 4.48 |
| 2012-12-31 | 10.45 | -23.43 | 24.86 | 3.67 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Sientra has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Sientra has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Sientra improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Sientra's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Sientra has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
SIEN Health
How is Sientra's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Sientra's finances.
The net worth of a company is the difference between its assets and liabilities.
- Sientra is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Sientra's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Debt is covered by short term assets, assets are 3.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Sientra Company Filings, last reported 2 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 42.23 | 59.78 | 61.96 |
| 2018-12-31 | 66.88 | 34.75 | 86.90 |
| 2018-09-30 | 87.98 | 34.72 | 103.01 |
| 2018-06-30 | 102.91 | 34.70 | 112.62 |
| 2018-03-31 | 9.84 | 27.99 | 16.06 |
| 2017-12-31 | 27.62 | 24.64 | 26.59 |
| 2017-09-30 | 43.61 | 24.75 | 37.64 |
| 2017-06-30 | 55.84 | 5.00 | 55.50 |
| 2017-03-31 | 74.27 | 0.00 | 58.76 |
| 2016-12-31 | 83.62 | 0.00 | 67.21 |
| 2016-09-30 | 91.07 | 0.00 | 79.28 |
| 2016-06-30 | 98.89 | 0.00 | 86.16 |
| 2016-03-31 | 108.13 | 0.00 | 93.49 |
| 2015-12-31 | 118.87 | 0.00 | 112.80 |
| 2015-09-30 | 146.49 | 25.14 | 148.94 |
| 2015-06-30 | 90.44 | 25.69 | 89.66 |
| 2015-03-31 | 92.84 | 25.56 | 93.59 |
| 2014-12-31 | 95.64 | 25.43 | 96.73 |
| 2014-09-30 | 21.55 | 25.30 | 19.82 |
| 2014-06-30 | 22.83 | 25.18 | 21.64 |
| 2014-03-31 | 22.91 | 15.20 | 9.47 |
| 2013-12-31 | 23.78 | 15.09 | 9.72 |
| 2012-12-31 | 42.82 | 0.00 | 39.21 |
- Sientra's level of debt (88.9%) compared to net worth is high (greater than 40%).
- The level of debt compared to net worth has increased over the past 5 years (66.8% vs 88.9% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Sientra has less than a year of cash runway based on current free cash flow.
- Sientra has less than a year of cash runway if free cash flow continues to grow at historical rates of 27% each year.
Financial health checks
We assess Sientra's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Sientra has a total score of 2/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
SIEN Dividends
What is Sientra's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
Sientra
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Sientra's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Sientra's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 9 Analyst Estimates (S&P Global) | See Below |
| United States of America Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 24 Stocks | 1.2% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 2011 Stocks | 2.5% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Sientra has not reported any payouts.
- Unable to verify if Sientra's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Sientra's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Sientra afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Sientra has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
SIEN Management
CEO
| COMPENSATION | $2,997,871 |
| AGE | 71 |
| TENURE AS CEO | 3.6 years |
CEO Bio
Mr. Jeffrey M. Nugent, also known as Jeff, has been the Chairman and Chief Executive Officer at Sientra, Inc. since November 12, 2015. Mr. Nugent has been a Director of Sientra, Inc. since July 2014. He served as an Acting Chief Executive Officer at Biolase, Inc. from June 16, 2014 to September 2, 2014 and served as its Chief Executive Officer and President from September 2, 2014 to July 13, 2015. Mr. Nugent served as Interim President at Biolase, Inc. since June 2014. He was the Founder, President and Chief Executive Officer at Precision Dermatology, Inc. from December 2010 to February 13, 2013 and served as its Senior Advisor. He served as President and Chief Executive Officer at Revlon Consumer Products Corp. since December 1999. From December 5, 1999 to 2002, he served as President and Chief Executive Officer at Revlon Inc. Mr. Nugent served as Worldwide President and Chief Executive Officer at Neutrogena until 1999. He served as Chairman, President and Chief Executive Officer of a number of pharmaceutical, medical device and consumer focused companies including Bioform, Inc. Mr. Nugent began his career at Johnson & Johnson, where he held senior responsibilities in general management, research, finance, marketing and manufacturing across pharmaceutical, medical device and consumer franchises. He served as Vice President at Worldwide Quality, where he led a corporate competitiveness improvement initiative. He served as an Artillery Officer in the U.S. Army and assigned to military intelligence at the Pentagon. He serves as the Chairman of Ascension Orthopedics. Mr. Nugent has been a Director at Merz Aesthetics, Inc. since February 6, 2009 and Neothetics, Inc. since September 23, 2015. He serves as a Member of Advisory Council at Winona Capital Management, LLC. He served as an Executive Chairman and Executive Director of Ventus Medical, Inc. He served as Chairman and Director of TRIA Beauty, Inc. He served on the Board of the Child Welfare League of America. He served as a Director of myoscience, Inc. He served as a Director of Revlon, Inc. since February 14, 2000, Revlon Consumer Products Corp. since February 2000 and BIOLASE, Inc. since March 6, 2014. He served as a Director of PreCision Dermatology, Inc. and Bioform, Inc. Mr. Nugent holds a B.S. in Mathematics from St. Joseph's College and earned an M.B.A. in Finance and Marketing from Loyola University in Chicago.
CEO Compensation
- Jeff's compensation has increased whilst company is loss making.
- Jeff's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the Sientra management team in years:
- The average tenure for the Sientra management team is less than 2 years, this suggests a new team.
Management Team
Jeff Nugent
Chairman & CEO
$3M
71
3.6 yrs
Paul Little
CFO, Senior VP & Treasurer
$2M
53
0.8 yrs
Charles Huiner
COO and Senior VP of Corporate Development & Strategy
$1M
47
3.4 yrs
Keith Sullivan
Director & Advisor to MiraDry Business
$1M
60
0.8 yrs
Deborah Bettencourt
Vice President of Customer Experience & Corporate Administration
Neil Bhalodkar
Senior Director of Investor Relations and Business Analytics
0.7 yrs
Oliver Bennett
General Counsel and VP of Compliance & Legal
1.4 yrs
Jason O’Hearn
Vice President of Sales & Professional Relations
Jane Wolf
Vice President of Marketing
0.5 yrs
Valerie Miller
VP & Corporate Controller
54
1.3 yrs
Board of Directors Tenure
Average tenure and age of the Sientra board of directors in years:
- The tenure for the Sientra board of directors is about average.
Board of Directors
Jeff Nugent
Chairman & CEO
$3M
71
3.6 yrs
Nick Simon
Lead Independent Director
$198K
64
3.6 yrs
Kevin O'Boyle
Director
$189K
62
4.9 yrs
Philippe Schaison
Director
$296K
56
2.3 yrs
Tim Haines
Director
$174K
60
5.7 yrs
Keith Sullivan
Director & Advisor to MiraDry Business
$1M
60
1.8 yrs
Mary Fisher
Director
0.4 yrs
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by Sientra insiders in the past 3 months.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 11. Jun 19 | Buy | Keith Sullivan | Individual | 07. Jun 19 | 07. Jun 19 | 20,869 | $5.75 | $119,997 | ||
| 11. Jun 19 | Buy | Paul Little | Individual | 07. Jun 19 | 07. Jun 19 | 17,391 | $5.75 | $99,998 | ||
| 11. Jun 19 | Buy | Kevin O'Boyle | Individual | 07. Jun 19 | 07. Jun 19 | 8,696 | $5.75 | $50,002 | ||
| 11. Jan 19 | Buy | Clarus Ventures, LLC | Company | 04. Jan 19 | 04. Jan 19 | 2,730,765 | $18.31 | $49,999,999 | ||
| 06. Sep 18 | Sell | Jeffrey Nugent | Individual | 31. Aug 18 | 31. Aug 18 | -1,852 | $24.90 | $-46,115 | ||
Management checks
We assess Sientra's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Sientra has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
SIEN News
Simply Wall St News
You Might Like Sientra, Inc. (NASDAQ:SIEN) But Do You Like Its Debt?
SIEN’s Debt (And Cash Flows) SIEN has built up its total debt levels in the last twelve months, from US$28m to US$60m , which includes long-term debt. … At the current liabilities level of US$77m, it seems that the business has maintained a safe level of current assets to meet its obligations, with the current ratio last standing at 1.52x. … Next Steps: Although SIEN’s debt level is towards the higher end of the spectrum, its cash flow coverage seems adequate to meet obligations which means its debt is being efficiently utilised.
Simply Wall St - – Full articleHow Do Analysts See Sientra, Inc. (NASDAQ:SIEN) Performing Over The Next Few Years?
Sientra, Inc.'s (NASDAQ:SIEN) most recent earnings update in December 2018 … company earnings became less negative compared to the previous year's level
Simply Wall St - – Full articleCan You Imagine How Sientra's (NASDAQ:SIEN) Shareholders Feel About The 36% Share Price Increase?
Given that Sientra didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.
Simply Wall St - – Full articleIs Sientra, Inc.'s (NASDAQ:SIEN) Balance Sheet Strong Enough To Weather A Storm?
(NASDAQ:SIEN) with its market cap of US$323m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Companies operating in the Medical Equipment industry,. … Evaluating financial health as part of your investment thesis is
Simply Wall St - – Full articleDid Sientra, Inc. (NASDAQ:SIEN) Insiders Buy Up More Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. … Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. … We generally consider it a positive if insiders have been buying on market, even above the current price.
Simply Wall St - – Full articleOur Take On Sientra Inc's (NASDAQ:SIEN) CEO Salary
This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Jeff Nugent's Compensation Compare With Similar Sized Companies. … Our data indicates that Sientra Inc is worth US$494m, and total annual CEO compensation is US$2.5m.
Simply Wall St - – Full articleAre Sientra Inc's (NASDAQ:SIEN) Interest Costs Too High?
While small-cap stocks, such as Sientra Inc (NASDAQ:SIEN) with its market cap of US$532m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn. … Evaluating financial health as part of your investment thesis is
Simply Wall St - – Full articleMarket Sentiment Around Loss-Making Sientra Inc (NASDAQ:SIEN)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. … The company’s loss has recently broadened since it announced a -US$64.03m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$72.03m, moving it further away from breakeven? … I’ve put together a brief outline of industry analyst expectations for SIEN, its year of breakeven and its implied growth rate.
Simply Wall St - – Full articleHow Do Analysts See Sientra Inc (NASDAQ:SIEN) Performing Over The Next Year?
To understand the overall trajectory of SIEN's earnings growth over these next fews years, I've fitted a line through these analyst earnings forecast to determine an annual growth rate from the slope. … NasdaqGS:SIEN Future Profit Mar 20th 18 This results in an annual growth rate of 28.37% based on the most recent earnings level of -US$64.03M to the final forecast of -US$101.81M by 2021. … Future Earnings: How does Sientra's growth rate compare to its peers and the wider market?
Simply Wall St - – Full articleHas Sientra Inc (SIEN) Improved Earnings Growth In Recent Times?
Check out our latest analysis for Sientra Did SIEN beat its long-term earnings growth trend and its industry? … For the purpose of this commentary, I like to use data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … For Sientra, the most recent twelve-month earnings -$54M, which, relative to the previous year’s level, has become less negative.
Simply Wall St - – Full articleSIEN Company Info
Description
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Details
| Name: | Sientra, Inc. |
| SIEN | |
| Exchange: | NasdaqGS |
| Founded: | 2003 |
| $318,425,604 | |
| 49,215,704 | |
| Website: | http://sientra.com |
| Address: |
Sientra, Inc. 420 South Fairview Avenue, Suite 200, Santa Barbara, California, 93117, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGS | SIEN | Common Stock | Nasdaq Global Select | US | USD | 30. Oct 2014 | |
| DB | S0Z | Common Stock | Deutsche Boerse AG | DE | EUR | 30. Oct 2014 |
Number of employees
Current staff
Industry
| Health Care Supplies | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/06/17 01:01 |
| End of day share price update: | 2019/06/14 00:00 |
| Last estimates confirmation: | 2019/06/06 |
| Last earnings filing: | 2019/05/08 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
